MDR - Comprehensive Reverse/Versa Dial Ti Glenosphere
← catalyst calendarNCT04003272 · readout in 2,922 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
59estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-10-28 | actual | When the study began enrolling |
| Primary completion | 2034-08-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2035-09-01 | estimated | The whole study's end, after follow-up |
| First posted | 2019-07-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Shoulder Pain
- Shoulder Injuries
- Shoulder Fractures
- Shoulder Arthritis
- Shoulder Disease
Intervention
- Device: Comprehensive Reverse Versa-Dial Titanium Glenosphere
Primary outcome
what the primary-completion date above is the date OFProduct Safety assessed through the incidence and frequency of revisions, complications and adverse events
measured Out to 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed